Alpine Immune Sciences (ALPN) announced the appointment of Wolfgang Dummer to chief medical officer effective October 2. He succeeds Andrew Sandler, who will transition responsibilities to Dummer through the remainder of the year. He joins Alpine from Rigel Pharmaceuticals (RIGL), where he served as chief medical officer.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on ALPN:
- Alpine Immune Sciences price target raised to $22 from $14 at Oppenheimer
- Alpine Immune Sciences initiates second dosing cohort in RUBY-3 study
- Alpine Immune Sciences price target raised to $17 from $11 at H.C. Wainwright
- Alpine Immune Sciences reports Q2 EPS (27c), consensus (37c)
- Is ALPN a Buy, Before Earnings?